We are live on ! Find out more
HQL

abrdn Life Sciences Investors

56 hedge funds and large institutions have $54.8M invested in abrdn Life Sciences Investors in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more capital invested

Capital invested by funds: $49.3M → $54.8M (+$5.47M)

5% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 20

0.28% less ownership

Funds ownership: 14.82%14.53% (-0.28%)

5% less funds holding

Funds holding: 5956 (-3)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

Holders
56
Holders Change
-3
Holders Change %
-5.08%
% of All Funds
1.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
21
Reduced
20
Closed
8
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q1 2019 in Review

56 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q1 2019, worth a combined $54.8M — up 11% from $49.3M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of HQL and 5 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 21 added.

The largest buyer was Wolverine Asset Management, adding an estimated $756K. The largest seller was Morgan Stanley, cutting an estimated $660K.

  • 56 institutional investors held abrdn Life Sciences Investors (HQL) as of Q1 2019, down from 59 in Q4 2018.
  • Funds reported $54.8M of abrdn Life Sciences Investors stock for Q1 2019, up 11% quarter-over-quarter.
  • 5 funds opened new abrdn Life Sciences Investors positions in Q1 2019 and 8 closed out, a net change of -3 holders.
  • The largest abrdn Life Sciences Investors buyer in Q1 2019 was Wolverine Asset Management, an estimated $756K added.
  • The largest abrdn Life Sciences Investors seller in Q1 2019 was Morgan Stanley, an estimated $660K sold.

Based on aggregated 13F filings for Q1 2019.